[Contribution of amniocentesis to prenatal screening of neural tube closing defects: evaluation of 10 years of a center's experience].
The authors report retrospective data on analysis of amniotic fluid DFTN markers (AFP and AChE) from 306 cases. Data were obtained from 261 amniocentesis done because there was a recurrence risk of DFTN and from 45 amniocentesis done because an anomaly as DFTN was diagnosed with ultrasonography. Results first show that the risk of recurrence is 3.03% in Rhône-Alpes area. In utero exposure to valproate appears as new indication for amniocentesis, in view of the possible association between Spina-Bifida and prenatal-valproate exposure (1/8 in the study). In contrast to anencephaly, Spina Bifida can be difficult to diagnose with ultrasonography before 20 weeks and require amniocentesis with AFP and AChE study.
S
S
Guibaud
M
M
Capella-Bonnet
A
A
Simplot
D000110:Acetylcholinesterase / Q000032:analysis; D000649:Amniocentesis; D000757:Anencephaly / Q000175:diagnosis; D005260:Female; D006801:Humans; D009436:Neural Tube Defects / Q000175:diagnosis*; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011296:Prenatal Diagnosis; D012189:Retrospective Studies; D012306:Risk; D016136:Spina Bifida Occulta / Q000175:diagnosis; D014463:Ultrasonography; D000509:alpha-Fetoproteins / Q000032:analysis
D000509:alpha-Fetoproteins; D000110:Acetylcholinesterase
Apport de l'amniocentèse au dépistage prénatal des défauts de fermeture du tube neural: bilan de 10 ans d'expérience d'un centre lyonnais.